Cargando…
Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration
BACKGROUND: Breast cancer incidence and mortality vary significantly among different nations and racial groups. African nations have the highest breast cancer mortality rates in the world, even though the incidence rates are below those of many nations. Differences in disease progression suggest tha...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4787041/ https://www.ncbi.nlm.nih.gov/pubmed/26964534 http://dx.doi.org/10.1186/s12885-016-2204-6 |
_version_ | 1782420644921606144 |
---|---|
author | Sawe, Rispah T. Kerper, Maggie Badve, Sunil Li, Jun Sandoval-Cooper, Mayra Xie, Jingmeng Shi, Zonggao Patel, Kirtika Chumba, David Ofulla, Ayub Prosperi, Jenifer Taylor, Katherine Stack, M. Sharon Mining, Simeon Littlepage, Laurie E. |
author_facet | Sawe, Rispah T. Kerper, Maggie Badve, Sunil Li, Jun Sandoval-Cooper, Mayra Xie, Jingmeng Shi, Zonggao Patel, Kirtika Chumba, David Ofulla, Ayub Prosperi, Jenifer Taylor, Katherine Stack, M. Sharon Mining, Simeon Littlepage, Laurie E. |
author_sort | Sawe, Rispah T. |
collection | PubMed |
description | BACKGROUND: Breast cancer incidence and mortality vary significantly among different nations and racial groups. African nations have the highest breast cancer mortality rates in the world, even though the incidence rates are below those of many nations. Differences in disease progression suggest that aggressive breast tumors may harbor a unique molecular signature to promote disease progression. However, few studies have investigated the pathology and clinical markers expressed in breast tissue from regional African patient populations. METHODS: We collected 68 malignant and 89 non-cancerous samples from Kenyan breast tissue. To characterize the tumors from these patients, we constructed tissue microarrays (TMAs) from these tissues. Sections from these TMAs were stained and analyzed using immunohistochemistry to detect clinical breast cancer markers, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 receptor (HER2) status, Ki67, and immune cell markers. RESULTS: Thirty-three percent of the tumors were triple negative (ER-, PR-, HER2-), 59 % were ER+, and almost all tumors analyzed were HER2-. Seven percent of the breast cancer patients were male, and 30 % were <40 years old at diagnosis. Cancer tissue had increased immune cell infiltration with recruitment of CD163+ (M2 macrophage), CD25+ (regulatory T lymphocyte), and CD4+ (T helper) cells compared to non-cancer tissue. CONCLUSIONS: We identified clinical biomarkers that may assist in identifying therapy strategies for breast cancer patients in western Kenya. Estrogen receptor status in particular should lead initial treatment strategies in these breast cancer patients. Increased CD25 expression suggests a need for additional treatment strategies designed to overcome immune suppression by CD25+ cells in order to promote the antitumor activity of CD8+ cytotoxic T cells. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2204-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4787041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47870412016-03-12 Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration Sawe, Rispah T. Kerper, Maggie Badve, Sunil Li, Jun Sandoval-Cooper, Mayra Xie, Jingmeng Shi, Zonggao Patel, Kirtika Chumba, David Ofulla, Ayub Prosperi, Jenifer Taylor, Katherine Stack, M. Sharon Mining, Simeon Littlepage, Laurie E. BMC Cancer Research Article BACKGROUND: Breast cancer incidence and mortality vary significantly among different nations and racial groups. African nations have the highest breast cancer mortality rates in the world, even though the incidence rates are below those of many nations. Differences in disease progression suggest that aggressive breast tumors may harbor a unique molecular signature to promote disease progression. However, few studies have investigated the pathology and clinical markers expressed in breast tissue from regional African patient populations. METHODS: We collected 68 malignant and 89 non-cancerous samples from Kenyan breast tissue. To characterize the tumors from these patients, we constructed tissue microarrays (TMAs) from these tissues. Sections from these TMAs were stained and analyzed using immunohistochemistry to detect clinical breast cancer markers, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 receptor (HER2) status, Ki67, and immune cell markers. RESULTS: Thirty-three percent of the tumors were triple negative (ER-, PR-, HER2-), 59 % were ER+, and almost all tumors analyzed were HER2-. Seven percent of the breast cancer patients were male, and 30 % were <40 years old at diagnosis. Cancer tissue had increased immune cell infiltration with recruitment of CD163+ (M2 macrophage), CD25+ (regulatory T lymphocyte), and CD4+ (T helper) cells compared to non-cancer tissue. CONCLUSIONS: We identified clinical biomarkers that may assist in identifying therapy strategies for breast cancer patients in western Kenya. Estrogen receptor status in particular should lead initial treatment strategies in these breast cancer patients. Increased CD25 expression suggests a need for additional treatment strategies designed to overcome immune suppression by CD25+ cells in order to promote the antitumor activity of CD8+ cytotoxic T cells. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2204-6) contains supplementary material, which is available to authorized users. BioMed Central 2016-03-10 /pmc/articles/PMC4787041/ /pubmed/26964534 http://dx.doi.org/10.1186/s12885-016-2204-6 Text en © Sawe et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Sawe, Rispah T. Kerper, Maggie Badve, Sunil Li, Jun Sandoval-Cooper, Mayra Xie, Jingmeng Shi, Zonggao Patel, Kirtika Chumba, David Ofulla, Ayub Prosperi, Jenifer Taylor, Katherine Stack, M. Sharon Mining, Simeon Littlepage, Laurie E. Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration |
title | Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration |
title_full | Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration |
title_fullStr | Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration |
title_full_unstemmed | Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration |
title_short | Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration |
title_sort | aggressive breast cancer in western kenya has early onset, high proliferation, and immune cell infiltration |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4787041/ https://www.ncbi.nlm.nih.gov/pubmed/26964534 http://dx.doi.org/10.1186/s12885-016-2204-6 |
work_keys_str_mv | AT sawerispaht aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration AT kerpermaggie aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration AT badvesunil aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration AT lijun aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration AT sandovalcoopermayra aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration AT xiejingmeng aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration AT shizonggao aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration AT patelkirtika aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration AT chumbadavid aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration AT ofullaayub aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration AT prosperijenifer aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration AT taylorkatherine aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration AT stackmsharon aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration AT miningsimeon aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration AT littlepagelauriee aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration |